Short-time infusion of oxaliplatin in combination with capecitabine (XELOX₃₀) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil

摘要

Background: The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established. Oxaliplatin induces acute, cold-induced neuropathy in most patients. The incidence is claimed to be infusion rate-dependent and therefore a 2-h infusion is recommended.